EP-1611: HDR intestinal brachytherapy as a salvage treatment in rectal adenocarcinoma patients  by Kazberuk, D.K. et al.
S882                                                                                                                                         3rd ESTRO Forum 2015 
 
 
 
 
 
Simulation phase: given the statistical nature of these 
relationships, we reserved one cartridge of each connectors 
type to assure that we would not run out of them when the 
surgical procedure took place. A retrospectively application 
of these formulae yielded that we would had used only those 
corresponding A, B, C reserved cartridges in 14%, 19% and 
12% of the procedures. We would have had only to add that 
spent cartridge when placing the following order. 
Conclusions: When LDR-brachytherapy seeds implant with 
needle loading on demand technique is used the quantity of 
the different types of seed connectors can be statistically 
expressed in terms of the preoperative prostate volume. With 
enough experience in the implant technique and preoperative 
prostate volumetric study it is possible to mark out 
institution-specific bounds to each of these quantities. It 
optimizes the preoperative prediction of seeds connectors, 
seeds and needles that will be used and reduces costs in 
material and storage.  
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Purpose/Objective: To analyze the twelve years outcomes of 
I-125 LDR brachytherapy in Turkish men with low-
intermediate risk localized prostate cancer.  
Materials and Methods: Between 2000-2004, 139 patients 
treated with LDR brachytherapy were analyzed 
retrospectively. Brachytherapy was monotherapy in 127 
pts.and used with external beam radiotherapy in 12 pts. Four 
pts excluded from study due to protocol deviation. 135 pts 
were analyzed for disease control and survival. For all the pts 
preplanning was done in treatment conditions. During the 
aplication real time planning was used. Four- six weeks after 
application postplanning dosimetry was done with CT and MR 
images. In dosimetry D90, V100, V150, V200, V250 for 
prostate; V100, V150 for urethra ; V100, dose at 4 cc for 
rectum were evaluated. Survival curves were calculated using 
the Kaplan- Meier method, and the significance was 
calculated by the log-rank test. To compare the prognostic 
factors Chi- square test was used.  
Results: The median follow-up time was 88 months ( 6-170 
months). The median age of 135 pts. Was 65 years (44-81 
years). In pts 64.4 % of them were in low risk and 35.6 % in 
intermediate risk. The mean PSA value at diagnosis was 8,12 
ng/ml (SD ±6,33). In 43.2 % of the pts received androgen 
deprivation for 3 months before procedure . T stages were 
T1c in 12 pts, T2a in 64 pts, T2b in 53 pts and T3 in 6 pts. 
During procedure median 28 (18-35) needles and 85 (65-110) 
seeds at 0.49 U/seed(0.43-0.50) were used. Prescribed dose 
was set at 145 Gy in monotherapy and 110 Gy in combined 
treatment. Treatment results were given in table 1.  
 
 
 
Conclusions: Our results are in concordance and comparable 
with other reports on I-125 LDR prostate brachytherapy. 
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Purpose/Objective: To analyze efficacy and toxicity profile 
of intestinal HDR brachytherapy in rectal Adenocarcinoma 
patients after tumorectomy as a salvage treatment. 
Materials and Methods: Between April 2009 and July 2014 15 
patients (pts) with adenocarcinoma underwent conformal 
HDR brachytherapy (HDR-BRT) with a temporary intestinal 
implants (2-7 catheters). The mean age of pts was 70,47 ( 
range 45-87). Twelve of patients received 30 Gy in 5 days (3 
Gy per fraction) twice daily. One patient received 24 Gy in 6 
days (4 Gy per fraction). One patient received 10 Gy in single 
fraction. One patient received 15 Gy in five days (3 Gy per 
3rd ESTRO Forum 2015                                                                                                                                         S883 
 
fraction).The dose was calculated based on 3D CT-planning 
using Oncentra Master Plan and PLATO planning software. 
Dose volume constrains which were analyzed for target were: 
V100, V150, V200, D90. Patients were monitored weekly 
during radiotherapy and 1,3,6,9 and 15 months after the end 
of the treatment and then at three months interval. Follow-
up visit included physical examination, images: ultrasound of 
abdomen and chest X ray and CEA value assessment. The 
acute toxicities were graded according to the EORTC/RTOG 
scales. 
Results: Median follow up was 34,4 months (range 18-58). 
Three local recurrences were observed. One patient died of 
intercurrent disease 12 months after the implantation which 
was unrelated to the brachytherapy. Grade 1 and 2 rectal 
toxicity was reported in ten patients ( 66,7%). Four patients 
(26.6%) reported Grade 3 toxicity. One patient (6,7%) 
required hospitalization and surgical intervention. The most 
common rectal symptoms were pain, bleeding, thin stool, 
rectal urgency and frequency and acute proctitis. However 
no fatal toxicity was observed. 
Conclusions: HDR brachytherapy is a valid anal sphincter 
sparing treatment modality to carefully selected patients and 
can be successfully used for salvage in patients with no other 
treatment options. The treatment was well tolerated by 
majority of patients with acceptable degree of acute 
toxicities. Overall survival data need longer follow-up. 
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Purpose/Objective: develop a method of intraluminal 
radiotherapy for esophageal cancer. 
Materials and Methods: In RCRC 52 inoperable patients with 
esophageal cancer were treated with the use of 1 step 
method intraluminal radiotherapy esophagus. In 63.4% of 
patients - constrictive inoperable esophageal cancer, at 
36.6% - a recurrence of esophageal cancer after treatment. 
Morphologically, the tumor shows squamous cell carcinoma 
(55.8%) and adenocarcinoma of varying degrees of 
differentiation (44.2%). In 84.6% of cases of marked 
dysphagia II-IV degree. Conducting topometricheskogo 
planning endovascular office allows you to set the Intrastat 
for the intraluminal radiotherapy in residual lumen of the 
esophagus to 1mm. Irradiation is performed with high activity 
sources Ir192. Dosing at 1 cm from the active line, the length 
of the active line 5-16sm. Treatment is carried out in 3 
fractions with an interval of 6-7 days ROD = 7Gr SOD = 
35games. In 96.2% of patients treated as outpatients 
conducted. After a 2-week break in 80.8% of cases to pursue 
further therapy: 52% rate teletherapy ROD = 2g = 80iGr to 
SOD, in 28.8% of cases in combination with chemotherapy. 
Follow-up of 4-26 months. In all cases observed treatment 
effect (tumor resorption in 23.1% - the complete destruction 
of the tumor, reducing the severity of dysphagia). 
Complications: 23.1% of the cases of different severity of 
esophagitis (docked conservative), 1.9% (1 patient) - 
esophago-tracheal fistula (setting 'covering' nitinol stent). 
Results: Follow-up of 4-26 months. In all cases observed 
treatment effect (tumor resorption in 23.1% - the complete 
destruction of the tumor, reducing the severity of 
dysphagia). Complications: 23.1% of the cases of different 
severity of esophagitis (docked conservative), 1.9% (1 
patient) - esophago-tracheal fistula (setting 'covering' nitinol 
stent). 
Carrying on 1 stage esophageal intraluminal radiotherapy 
reduces the severity of dysphagia, which contributes to the 
correction of metabolic disorders and improve the overall 
condition, creates the possibility of external beam 
radiotherapy and chemotherapy in patients previously 
considered incurable, and consequently improves the results 
of treatment. 
Conclusions: Intraluminal radiotherapy of the esophagus is a 
highly effective and safe treatment for patients with 
inoperable cancer of the esophagus, especially combines with 
dysphagia tumor genesis, significantly improving the quality 
of life and its duration in these patients. 
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Purpose/Objective: The purpose of this study is to compare 
high frequency ultrasonography (HFUS) and histpathologic 
assessment done by punch biopsy to determine depth of basal 
cell carcinoma (BCC), in both superficial and nodular BCCs 
prior to brachytherapy treatment. 
Materials and Methods: This study includes 20 patients with 
10 superficial and 10 nodular BCCs. First, punch biopsy was 
done to confirm the diagnosis and to measure tumour depth 
(Breslow rate). Subsequently, HFUS was done to measure 
tumour depth to search for correlation of these two 
techniques. 
